R Mahadeo1, S Gounder1, S M Graham2. 1. National Tuberculosis Programme, Ministry of Health, Suva, Fiji. 2. Centre for International Child Health, University of Melbourne and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Victoria, Australia ; International Union Against Tuberculosis and Lung Disease, Paris, France.
Abstract
BACKGROUND: Fixed-dose combinations (FDCs) of first-line anti-tuberculosis drugs were introduced in Fiji in 2011, and there have been concerns about treatment response. OBJECTIVE: To evaluate the treatment response to FDCs among tuberculosis (TB) patients. METHODS: A retrospective cohort study was undertaken of treatment outcomes of new TB cases registered from January 2010 to April 2013 and weighing ⩾30 kg. Sputum smear conversion of new sputum smear-positive cases and end-of-treatment outcomes of all cases were evaluated for those receiving FDCs and compared to outcomes with previous use of single-drug preparations. RESULTS: Among new TB patients, 240 received single-drug preparations and 259 received FDCs for the full duration of treatment. The groups were similar in terms of demographic and clinical characteristics. Treatment outcomes were available for 95% of cases. Unknown outcomes were more common in those receiving FDCs. When known, end-of-treatment outcome was the same in the two treatment groups and did not differ between TB types. Sputum smear conversion after the 2-month intensive phase of treatment was similar in the two treatment groups: 95% and 97%, respectively. CONCLUSION: The introduction of FDCs in Fiji for the treatment of TB cases has not been associated with changes in treatment response.
BACKGROUND: Fixed-dose combinations (FDCs) of first-line anti-tuberculosis drugs were introduced in Fiji in 2011, and there have been concerns about treatment response. OBJECTIVE: To evaluate the treatment response to FDCs among tuberculosis (TB) patients. METHODS: A retrospective cohort study was undertaken of treatment outcomes of new TB cases registered from January 2010 to April 2013 and weighing ⩾30 kg. Sputum smear conversion of new sputum smear-positive cases and end-of-treatment outcomes of all cases were evaluated for those receiving FDCs and compared to outcomes with previous use of single-drug preparations. RESULTS: Among new TB patients, 240 received single-drug preparations and 259 received FDCs for the full duration of treatment. The groups were similar in terms of demographic and clinical characteristics. Treatment outcomes were available for 95% of cases. Unknown outcomes were more common in those receiving FDCs. When known, end-of-treatment outcome was the same in the two treatment groups and did not differ between TB types. Sputum smear conversion after the 2-month intensive phase of treatment was similar in the two treatment groups: 95% and 97%, respectively. CONCLUSION: The introduction of FDCs in Fiji for the treatment of TB cases has not been associated with changes in treatment response.
Authors: Anthony D Harries; Rony Zachariah; Elizabeth L Corbett; Stephen D Lawn; Ezio T Santos-Filho; Rhehab Chimzizi; Mark Harrington; Dermot Maher; Brian G Williams; Kevin M De Cock Journal: Lancet Date: 2010-05-18 Impact factor: 79.321
Authors: Christian Lienhardt; Sharlette V Cook; Marcos Burgos; Victoria Yorke-Edwards; Leen Rigouts; Gladys Anyo; Sang-Jae Kim; Amina Jindani; Don A Enarson; Andrew J Nunn Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: Felix R Kayigamba; Mirjam I Bakker; Veronicah Mugisha; Ludwig De Naeyer; Michel Gasana; Frank Cobelens; Maarten Schim van der Loeff Journal: PLoS One Date: 2013-09-16 Impact factor: 3.240